Therapeutic-focused CRO Services

KCAS Bio has proven expertise across a range of disease and treatment areas. With more than 45 years of experience as a drug development CRO, we combine deep bioanalytical and biomarker experience with our reputation for consistency, transparency, and data integrity at every stage of your specific therapeutic focus area.

Talk to an expert

Therapeutic areas of focus

Allergy & immunology

We have extensive experience in developing, validating, and implementing immunological methods, including biomarker quantification and flow cytometry. Trust our team of experts to provide tailored solutions for your drug development needs.

Explore now
Oncology

KCAS Bio provides reliable data to advance immune-oncology treatments. From discovery to Phase III trials, we have experience in flow cytometry, ELISPOTs, and cell-based assays, alongside multiple biomarkers.

Explore now
Infectious diseases

In a post-COVID-19 world, trust a CRO with proven experience in infectious disease and vaccine development. KCAS stands ready, equipped with diverse platforms and techniques for your project success.

Explore now
Neurological

In a world witnessing a surge in brain disorders, our advanced neurosciences expertise is your ally from discovery to translation. Unlock the potential of neurological drug development with KCAS.

Explore now
Gastrointestinal

With a focus on experimental therapeutics, we address a spectrum of conditions including Crohn's disease and inflammatory bowel disease. Trust KCAS for a comprehensive approach to advance your project in the evolving landscape of gastrointestinal disorders.

Explore now
Ophthalmology

From compound identification to efficacy studies, we specialize in preclinical ophthalmic research. Our experienced team ensures milestone data accuracy for crucial early-stage decisions. Trust KCAS Bio for the complexities of your ophthalmology study.

Explore now
Rare diseases

Our validated 20-plex assay for 20 amino acids supports metabolism and rare disease research. Developing drugs for rare diseases demands specialized expertise, especially in cell and gene therapy. KCAS Bio stands out with a proven history and experience.

Explore now
Respiratory

We monitor immune system status during and after infection, offering flow cytometric immunophenotyping, cytokine profiling, and retrospective studies. With expertise in whole blood, PBMCs, and respiratory samples, we specialize in diseases like COPD, lung cancer, and pneumonia.

Explore now
Renal

Trust KCAS for expert renal/kidney testing. We develop assays, even for challenging compounds, ensuring quality data for drug development. With extensive experience, we understand the crucial role renal function plays in drug elimination.

Explore now
Cardiovascular

With 40+ years in pre-clinical research, we provide deep expertise in cardiovascular biomarkers and large molecule drugs. From target identification to drug development, trust us for comprehensive bioanalytical support at every stage of your cardiovascular drug project.

Explore now
Metabolic

Discover comprehensive support for metabolic drug development with KCAS. With a deep understanding of metabolic and endocrine diseases, we provide expert bioanalytical services from discovery to biologic development.

Explore now

Find exactly what you’re looking for

Search for specific services, platforms, instrumentation, or scientific insights.

Global Validation of a Pan-Leukocyte Panel with Enumeration for Fresh Whole Blood​ Posters & Papers
Read article Global Validation of a Pan-Leukocyte Panel with Enumeration for Fresh Whole Blood​

Discover in this poster presented by Heather Evans, PhD, at ICCS 2025, our work on the “Global Validation of a Pan-Leukocyte Panel with Enumeration for Fresh Whole Blood​“. Validation Pan-Leukocyte Panel Whole Blood KCAS BioDownload If you have any questions about these services…

Podcast (The Weekly Bioanalysis) Eps #93: “Collaborating with Smaller, Scientific Partners to Accelerate Drug Development” Podcasts
Read article Podcast (The Weekly Bioanalysis) Eps #93: “Collaborating with Smaller, Scientific Partners to Accelerate Drug Development”

During episode #93 of The Weekly Bioanalysis, John and Dom welcome guest Chris Crean, founder/CEO of Xyzagen, who reflects on three decades in drug development and how the field has shifted from small molecules to today’s complex biologics, gene editing, and beyond. Chris explains how Xyzagen helps small, science-driven teams…

Podcast (The Conversational Flow) Eps #24: “Considerations for Flow Cytometry-based Cell Sorting” Podcasts
Read article Podcast (The Conversational Flow) Eps #24: “Considerations for Flow Cytometry-based Cell Sorting”

In this episode, Adam and Brian explored recent advances in cell sorting technology, focusing on image-activated approaches. Unlike traditional flow cytometry, which relies on voltage signals, these systems capture and analyze cell images in real time to guide sorting decisions, enabling new insights such as subcellular localization and cell-to-cell signaling.

Agile, responsive, and easy to work with

We prepare and adapt our services based on a deep understanding of your drug development ambitions and wider business objectives.

Explore services